Category Archives: Research News (General)

More than 5 million Americans today are affected by Alzheimer’s disease (AD). It is estimated that there will be more than 16 million people with AD in the United States and more than 60 million people with AD worldwide by 2050. In the past 25 years, only five symptomatic medications for AD have met their primary clinical endpoints in Phase III clinical trials and successfully come to market; of these, four are still available.

There is increasing evidence that multiple medical conditions increase the risk of neurodegeneration and subsequent development of dementia. It also is becoming clear that a majority of those risk factors acts in amyloid- and tau-independent ways. Since 2003, every symptom- and disease-modifying agent has failed in Phase II or III trials because of challenges with safety or efficacy, including trials testing the amyloid hypothesis, anti-inflammatory agents, and early-phase anti-tau therapies.

With disease-modifying treatment trials unsuccessful at the present time and only medications to treat symptoms available, what now?

Thinking “out-of-the-box,” a scientist has developed an innovative program called the “Dementia Prevention Initiative” (DPI), which abandons generalized methods used to research and treat AD. The program has a novel “N-of-1 design” that individualizes medicine down to a single patient. Instead of conducting a conventional trial of 100 people all getting the same treatment, the scientist is conducting 100 single trials personalized to the individual. The youngest patient enrolled is 61 and the oldest is 86.

The DPI is a two-year clinical trial aimed at developing a best-practice model of personalized care that looks at each individual as the sole unit of observation. The idea is to treat neurodegenerative diseases as a disorder that develops over a lifetime and individualize ways to build a better brain as we age. The ultimate goal is to prevent dementia from happening in the first place.

The approach follows a form of personalized treatment similarly used in cancer and delivers an individualized prevention plan, tailored to each patient’s risk profile based on their genetic traits, biomarkers (blood, imaging, and electrophysiology), socio-demographics, lifestyle choices, and co-existent medical conditions. This approach specifically targets the heterogeneity of AD by identifying person-specific risk factors and applying a customized intervention directed against this risk profile. The head scientist anticipates that this method will provide more rapid information on whether personalized prevention plans can improve person-centered outcomes.

Although the single greatest risk factor for AD is age, AD is not inevitable. It is estimated that at age 85 there is a 42 percent risk of developing AD, which means that 58 percent of older adults do not develop dementia, even if amyloid can be detected in the brain. The reasons are unknown, but may be explained in part by a host of modifiable and non-modifiable risk factors. Up to 30 percent of AD cases may be preventable through modification of risk factors and behavioral changes to mitigate the effect of those risk factors that can’t be modified.

Nationally, if the onset of AD and related disorders is delayed by five years, 25 years later there would be approximately 5.7 million fewer cases, collective family savings would approach $87 billion, and societal savings would approach $367 billion.

Paper: “Prevention of Alzheimer’s Disease: Lessons Learned and Applied”

Reprinted from materials provided by Florida Atlantic University.

A new study shows that the taking of diabetes medicine reduces the risk of getting Parkinson´s disease.

Researchers have discovered that medical treatment against diabetes reduces the risk of getting Parkinson´s disease by 35 percent.

The researchers believe that diabetes medicines, containing glitazones, are influencing the cells to produce more mitochondria. Mitochondria are the powerhouse of the cells, transforming nutrients that the cells need to work.

The research group has previously shown that the production of mitochondria decreases during Parkinson´s.

To see the connection between diabetes and Parkinson´s, the researchers analysed and compared data from the Norwegian Prescription Data Base. The database has stored information on all use of prescription the last 10 years and contains data on more than 100 million prescriptions.

Paper: “Glitazone use associated with reduced risk of Parkinson’s disease”

Reprinted from materials provided by University of Bergen.

Increased communication between distant brain regions helps older adults compensate for the negative aspects of aging, reports a new study published this week in Human Brain Mapping.

The aged brain tends to show more bilateral communication than the young brain. While this finding has been observed many times, it has not been clear whether this phenomena is helpful or harmful and no study has directly manipulated this effect, until now.

The researchers used a brain stimulation technique known as transcranial magnetic stimulation (TMS) to modulate the brain activity of healthy older adults while they performed a memory task. When researchers applied TMS at a frequency that depressed activity in one memory region in the left hemisphere, communication increased with the same region in the right hemisphere, suggesting the right hemisphere was compensating to help with the task.

In contrast, when the same prefrontal site was excited, communication was increased only in the local network of regions in the left hemisphere. This suggested that communication between the hemispheres is a deliberate process that occurs on an “as needed” basis.

Furthermore, when the authors examined the white matter pathways between these bilateral regions, participants with stronger white matter fibers connecting left and right hemispheres demonstrated greater bilateral communication, strong evidence that structural neuroplasticity keeps the brain working efficiently in later life.

These results suggest that greater bilaterality in the prefrontal cortex might be the result of the aging brain adapting to the damage endured over the lifespan, in an effort to maintain normal function. Future brain-stimulation techniques could target this bilateral effect in effort to promote communication between the hemispheres and, hopefully, engender healthy cognition throughout the lifespan.

Paper: “Frequency-specific neuromodulation of local and distant connectivity in aging and episodic memory function”
Reprinted from materials provided by Duke University School of Medicine.

The brain’s own mechanisms for dealing with the loss of dopamine neurons in Parkinson’s disease may be a source of the disorder’s abnormal movement, according to a study published in Neuron.

The study suggests the loss of dopamine may cause the brain to rewire in a maladaptive manner, contributing to impaired movement in Parkinson’s disease. These findings also suggest that there are fundamental problems with scientists’ traditional model of Parkinson’s disease, according to the researchers.

The prevailing consensus was that excessive patterning of the subthalamic nucleus (STN), a component of the basal ganglia, by the cerebral cortex was linked to the symptomatic expression of Parkinson’s disease, including muscle rigidity and slowness of movement.

Thus, the researchers expected to see transmission in the cortex-to-STN pathway increase as dopamine levels dropped. Instead, they found the opposite: the strength of the pathway decreased massively.

Further investigation suggested abnormal activity in a more indirect pathway from the cortex to the STN, involving the globus pallidus, was responsible. Abnormal activity in the indirect pathway leaves the STN vulnerable to excessive excitation, triggering compensatory plasticity that ultimately proved to be harmful, according to the study.

When the scientists prevented this maladaptive plasticity in late-stage Parkinson’s models, they found the symptoms improved, pointing to a link between compensation and motor dysfunction.

While the compensatory mechanisms may initially keep the brain operating normally under conditions of moderate dopamine neuron loss, as the disease progresses and more dopamine neurons die, the adaptations may become so extreme that they impair movement, according to the study.

These results suggest that there are fundamental flaws in our traditional understanding of brain dysfunction in Parkinson’s disease.

Paper: “Loss of Hyperdirect Pathway Cortico-Subthalamic Inputs Following Degeneration of Midbrain Dopamine Neurons”
Reprinted from materials provided by Northwestern University.

Physical aggression among people with dementia is not unusual. A new study shows that one-third of those diagnosed with Alzheimer’s disease or frontotemporal dementia were physically aggressive towards healthcare staff, other patients, relatives, animals and complete strangers.

The study is based on a review of brain examinations and patient journals of 281 deceased people who were diagnosed with Alzheimer’s or frontotemporal dementia between the years 1967 and 2013. The researchers have followed the entire duration of the disease for this group, from the patients’ first contact with a physician to follow up after death.

According to the researchers, patients with frontotemporal dementia displayed physically aggressive behavior earlier in their disease than those diagnosed with Alzheimer’s. This could be due to the fact that frontotemporal dementia begins in the part of the brain responsible for, among other things, empathy, impulse control, personality and judgement.

The number of patients who displayed physical aggression was greater amongst those diagnosed with Alzheimer’s. However, individuals with frontotemporal dementia were physically aggressive more often — and the violence exhibited by the people suffering from frontotemporal dementia could also be more serious, and this was particularly evident towards complete strangers.

Twenty-one per cent of the physically aggressive patients with frontotemporal dementia were physically aggressive towards strangers, compared with two per cent of the physically aggressive Alzheimer patients, an unexpectedly large difference.

Patients with frontotemporal dementia tend to start showing symptoms at an earlier age than those with Alzheimer’s. There is also often a longer delay between the first symptoms and diagnosis. The scientists say that socially deviant or criminal behaviour in people who had not previously demonstrated such behaviours should be taken seriously, as it could be the first sign of dementia.

Paper: “Physical aggression among patients with dementia, neuropathologically confirmed post-mortem”
Reprinted from materials provided by Lund University.

A research team has identified a new mechanism that causes the hallmark symptoms of Parkinson’s disease, namely tremors, rigidity, and loss of voluntary movement.

The discovery presents a new perspective to three decades of conventional wisdom in Parkinson’s disease research. It also opens up new avenues that can help alleviate the motor problems suffered by patients of the disease, which reportedly number more than 10 million worldwide. The research was published in Neuron.

It is known that Parkinson’s disease is caused by a lack of dopamine, a chemical in the brain that transmits neural signals. However, it remains unknown how the disease causes the motor problems that plague Parkinson’s disease patients.

Smooth, voluntary movements, such as reaching for a cup of coffee, are controlled by the basal ganglia, which issue instructions via neurons (nerve cells that process and transmit information in the brain) in the thalamus to the cortex. These instructions come in two types: one that triggers a response (excitatory signals) and the other that suppresses a response (inhibitory signals). Proper balance between the two controls movement.

A low level of dopamine causes the basal ganglia to severely inhibit target neurons in the thalamus, called an inhibition. Scientists have long assumed that this stronger inhibition causes the motor problems of Parkinson’s disease patients.

To test this assumption, the research team used optogenetic technology in an animal model to study the effects of this increased inhibition of the thalamus and ultimately movement. Optogenetics is the use of light to control the activity of specific types of neurons within the brain.

They found that when signals from the basal ganglia are more strongly activated by light, the target neurons in the thalamus paradoxically became hyperactive. Called rebound excitation, this hyperactivity produced abnormal muscular stiffness and tremor. Such motor problems are very similar to the symptoms of Parkinson’s disease patients. When this hyperactivity of thalamic neurons is suppressed by light, mice show normal movements without Parkinson’s disease symptoms. Reducing the levels of activity back to normal caused the motor symptoms to stop, proving that the hyperactivity caused the motor problems experienced by Parkinson’s disease patients.

Paper: “Inhibitory Basal Ganglia Inputs Induce Excitatory Motor Signals in the Thalamus”

Reprinted from materials provided by the Korea Advanced Institute of Science and Technology.

Nearly a quarter century ago, a genetic variant known as ApoE4 was identified as a major risk factor for Alzheimer’s disease — one that increases a person’s chances of developing the neurodegenerative disease by up to 12 times. However, it was never clear why the ApoE4 variant was so hazardous.

Now, a study shows that the presence of ApoE4 exacerbates the brain damage caused by toxic tangles of a different Alzheimer’s-associated protein: tau. In the absence of ApoE, tau tangles did very little harm to brain cells.

The findings suggest that targeting ApoE could help prevent or treat the brain damage present in Alzheimer’s disease, for which there are currently no effective therapies.

Alzheimer’s, which affects one in 10 people over age 65, is the most common example of a family of diseases called tauopathies. To find out what effect ApoE variants have on tauopathies, the researchers turned to genetically modified mice that carry a mutant form of human tau prone to forming toxic tangles.

The researchers studied mice that lacked their own version of the mouse ApoE gene or mice with replacements of the three variants of the human ApoE gene: ApoE2, ApoE3 or ApoE4.

By the time the mice were 9 months old, those carrying human ApoE variants had widespread brain damage. ApoE4 mice exhibited the most severe neurodegeneration, and ApoE2 the least. The mice that lacked ApoE entirely showed virtually no brain damage.

Further, the immune cells in the brains of mice with ApoE4 turned on a set of genes related to activation and inflammation much more strongly than those from ApoE3 mice. Immune cells from mice lacking ApoE were barely activated.

Next, the researchers set out to determine whether ApoE in people similarly exacerbates neuronal damage triggered by tau. After studying autopsy samples from 79 people who died from tauopathies, they found that people with ApoE4 had more damage than those that lacked ApoE4.

These findings suggest that decreasing ApoE specifically in the brain could slow or block neurodegeneration, even in people who already have accumulated tau tangles. Most investigational therapies for Alzheimer’s disease have focused on amyloid beta or tau, and none has been successful yet in changing the trajectory of the disease. Targeting ApoE has not yet been tried.

Researchers are hopeful that if their findings are replicated, reducing ApoE in the brain in the early stages of neurodegenerative disease could prevent further neurodegeneration.

Paper: “ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy”
Reprinted from materials provided by Washington University School of Medicine.

Mutations in the human genome may be responsible for many diseases. In the case of Parkinson’s disease (PD), variants of ACMSD (aminocarboxymuconate semialdehyde decarboxylase), may be implicated in PD, but until now, no mutations in ACMSD had been found in any PD patients. In a study in the Journal of Parkinson’s Disease, researchers announce the discovery of a unique mutation in a 74-year-old man with PD. This mutation is not found in the neurologically normal population, and may be the first indication that rare variants in ACMSD alone might increase the risk of PD.

The novel ACMSD mutation was identified during a genetic screening study of 62 PD patients on the island of Menorca, which were matched with 192 ethnicity-matched neurologically normal individuals with no family history of PD. Genetic variants found in these individuals were checked against various databases to identify normal variations observed in other populations. While researchers found mutations already associated with PD, they discovered one novel mutation in the ACMSD gene in a single patient with no family history of PD and none of the known PD-related mutations found in other populations.

The ACMSD gene encodes for an enzyme in the kynurenine pathway, aminocarboxymuconate semialdehyde decarboxylase, involved in the metabolism of tryptophan. Some metabolites of the kynurenine pathway are known to play an important role in the central nervous system in both health and disease states. Specifically, ACMSD activity results in less accumulation of quinolinic acid which is a molecule known to have neurotoxic properties. Not only does quinolinic acid cause “excitotoxicity” (overstimulation of nerve cells leading to their death), but it can also directly activate the immune cells of the brain, i.e. microglia, and thereby trigger inflammation (already known to occur in PD). Therefore, there is a good pathobiological rationale for why reduced levels (due to the mutation) of functional ACMSD can result in the type of neurodegeneration seen in PD brains.

According to the researchers, these results could lead to a better understanding of the disease and, potentially, to the development of new therapeutic strategies.

Researchers have recently discovered a new mechanism for storing information in synapses and a means of controlling the storage process. The breakthrough helps clarify the mystery of the molecular mechanisms of memory and learning processes. The research appears in the journal Nature.

Communication between neurons passes through more than one million billion synapses, tiny structures the tenth of the width of a single hair, in an extremely complex process. Synaptic plasticity, by which synapses adapt to neuronal activity, was discovered nearly 50 years ago. Since then, the scientific community has considered it to be a vital functional component of memorisation and learning.

This new research has helped scientists better understand the basic mechanisms by which information is stored in the brain. Researchers used a combination of techniques based on chemistry, electrophysiology and high-resolution imaging to develop a new method to immobilise receptors at synaptic sites. This method successfully stops receptor movement, making it possible to study the impact of the immobilization on brain activity and learning ability. It provides evidence that receptor movement is essential to synaptic plasticity as a response to intense neuronal activity.

Researchers also explored the direct role of synaptic plasticity in learning. By teaching mice to recognize a specific environment, they show that halting receptor movement can be used to block the acquisition of this type of memory, confirming the role of synaptic plasticity in this process.

The discovery offers new perspectives on controlling memory.

Paper: “Hippocampal LTP and contextual learning require surface diffusion of AMPA receptors”
Reprinted from materials provided by CNRS.

Scientists have identified a toxic cascade that results in neuronal degeneration in people with Parkinson’s disease (PD) and have determined how to interrupt it, reports a study published in the journal Science.

Using an antioxidant to intervene early in the disease process may break the cycle of degeneration and improve the function of neurons in Parkinson’s, according to the study.

Using human neurons from Parkinson’s patients, the scientists identified a toxic cascade of mitochondrial and lysosomal dysfunction initiated by an accumulation of oxidized dopamine and a protein called alpha-synuclein. The study demonstrated that an accumulation of oxidized dopamine depressed the activity of lysosomal glucocerebrosidase (GCase), an enzyme implicated in PD. That depression in turn weakened overall lysosomal function and contributed to degeneration of neurons.

The accretion of oxidized dopamine didn’t just interfere with lysosomes, however. The scientists discovered that the dopamine also damaged the neurons’ mitochondria by increasing mitochondrial oxidant stress. These dysfunctional mitochondria led to increased oxidized dopamine levels, creating a vicious cycle.

After identifying the toxic cascade, the researchers looked for ways to disrupt it. They noted that by treating dopamine neurons with specific antioxidants early in the toxic cascade process attenuated or even prevented the downstream effects in human dopaminergic neurons. This approach may be a future therapy target. However, since neurodegeneration creates damage before symptoms are apparent, an antioxidant therapy may also require genetic testing and other screening measures such as brain imaging and other clinical signifiers to identify patients in the early stages of the disease.

Paper: “Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease”
Reprinted from materials provided by Northwestern University.